A First-in-Human Phase 1 Study of the Anti-LILRB4 Antibody IO-202…

Written By Mollie Rotmensch

DiNardo C. et al. A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML). Blood. 2020; 136 (Supplement 1): 19–20.

Mollie Rotmensch
Previous

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Next

Preclinical characterization of a novel therapeutic antibody targeting LILRB2